Exagen Launches AVISE SLE+ Connective Tissue 2.0

Contact: Blythe Lawton


Albuquerque, N.M., February 3, 2013 – Exagen Diagnostics Inc., a leading medical diagnostic company focused in rheumatology, today announced the launch of the new Avise SLE+ Connective Tissue 2.0 diagnostic.

Avise 2.0 is an enhanced version of Exagen’s comprehensive Connective Tissue Disease ( CTD) diagnostic that upgrades the original test to offer additional clinical utility for physicians. With 33% greater specificity than ANA and 48% greater sensitivity than dsDNA, as confirmed by Crithidia, Avise SLE+ Connective Tissue 2.0 offers a more accurate tool for physicians than the current diagnostic standard. The upgraded diagnostic delivers an overall performance of 80% sensitivity and 86% specificity through the integration of Extractable Nuclear Antigens (ENAs) and an upgraded testing algorithm which helps when distinguishing SLE from common CTD.

Other additions to the Avise 2.0 diagnostic include Thyroid Auto-Antibody testing, additional integration of biologically relevant CB-CAPs technology in our two-tier testing algorithm and ANA testing 2 ways; by IIF (Indirect Immunofluorescence) with patterns and by ELISA. Avise SLE+ Connective Tissue can assist physicians with the diagnosis of SLE/Lupus, Rheumatoid Arthritis, Sjogren’s syndrome, Systemic Sclerosis, Polymyositis/Dermatomyositis (PM/DM), Anti-Phospholipid Syndrome, Mixed Connective Tissue Disease (MCTD) and Autoimmune Thyroid Disease.

“We are pleased to offer additional value to our physicians with Avise SLE+ Connective Tissue 2.0 and to continue to help support them with their clinical assessment and treatment of patients,” said Ron Rocca, Exagen President, and CEO.

About Exagen

Exagen Diagnostics, Inc. is a Patient Focused, Discovery Driven, CLIA- certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. Committed to Personalized Medicine, our tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. For more information, please visit www.AviseTest.com. ###